2.34K
·
08-18
$TSM 20261002 360.0 PUT$ After booking my profits belore the pullback, now I'm opening new positions at a much better price and lucrative premium! Just few hours and TSM price started to recover and now generating profit.
TSM PUT
08-18 22:50
US20261002 360.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 3.60 3Lot(s) | +66.67% Holding |
4.02K
·
08-19
$SS SPDR STI ETF(ES3.SI)$ Good morning! Accumulating more shares of ES3. Good for long term investment + dividends. Good way to park extra money.[Shy] [Love you]
2.25K
·
08-19
$IONQ 20260828 39.0 PUT$ Limit order filled to sell IONQ cash secured put at strike $39 for credit. Below psychological $40 support level.
IONQ PUT
08-18 21:30
US20260828 39.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 0.52 1Lot(s) | +81.74% Holding |
1.86K
·
08-19
$AMD 20260821 450.0 PUT$ Naked put - hope it expires worthless I don't just want a lucky win—I want consistent profits. I'm willing to put in whatever effort is required to achieve that. My goal for Aug is to earn $10,000 (including premiums paid to close the options). June / Jul 2026: $1,721 / $26,431 Aug 2026: $26,296
AMD PUT
08-19 21:49
US20260821 450.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 3.05 1Lot(s) | -- Closed |
TOPdong123: I'm bullish on this setup too, but 440 feels cleaner than 450. Post-earnings AMD usually shakes weak hands before the premium really decays lol
1.48K
·
08-19
$DAR CALENDAR 260821/260918 CALL 60.0/CALL 60.0$ Rolled the call for another month. Could not get a better price as open interest is low.
DAR Calendar
08-19 22:41
US60.0/60.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Credit Close | -0.60 1 | -- Closed |
TOPLow OI makes rolls ugly fast. On DAR these calendar calls can get wide quick, so another month makes sense
5.96K
·
08-19
$COIN CALENDAR 260828/260821 PUT 150.0/PUT 150.0$ Order got filled because I forgot to cancel it LOL, well looks like we're off to a great start with a huuuugee green candle or BTC and COIN as well, filling the gap and potentially forming an island reversal pattern! Looks like dreams do come true after all.
COIN Calendar
08-19 21:30
US150.0/150.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Credit Close | -2.45 1 | -- Closed |
TOPBullish for sure, but island reversal only counts if volume actually confirms it. How big was the spike on that green candle?
1.60K
·
08-20
$AAOI 20260918 100.0 PUT$ selling put option to earn premium and intend to buy the share at this price
AAOI PUT
08-20 01:03
US20260918 100.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 4.15 1Lot(s) | -20.00% Holding |
TOP105 was fatter premium, but 100 gives cleaner assignment math. 4.15 for that cushion still looks pretty solid
3.62K
·
08-20
$Palantir Technologies Inc.(PLTR)$ I continue to average up my position in $Palantir(PLTR)$ because I'm investing in the long-term AI story, not simply chasing the recent price momentum. Palantir has built a strong position at the intersection of AI, data analytics and enterprise software, with its platforms becoming increasingly important for companies and governments looking to turn AI into real-world applications. For me, the key is that Palantir is not just an AI "story" — it has an established business, recurring customers and a platform that can potentially scale significantly as AI adoption accelerates. Another reason I'm comfortable averaging up is the company's execution. Palantir continues to demonstrate strong demand for its AI cap
PLTR
08-19 01:35
USPalantir Technologies Inc.
| Side | Price | Realized P&L |
|---|---|---|
| Buy Open | 172.83 | +8.34% Holding |
TOPLong term makes sense, but I care more about the commercial growth numbers if that side keeps outpacing government, the premium stays easier to justify
6.76K
·
08-20
$BABA 20260828 129.0 CALL$ 4th ticker i ever bought calls on. Pure earnings play. I am hoping that investors see the growth in their cloud business. Not to mention the advancements in their AI model, Qwen.
TOPCloud growth above 25% is the whole game here. If that holds, 140 feels more like timing than debate
3.49K
·
08-20
$RKLB 20260828 62.0 PUT$ Limit order filled to sell RKLB cash secured put for credit during RKLB price retracement.
RKLB PUT
08-19 21:49
US20260828 62.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 0.32 1Lot(s) | +93.75% Holding |
TOP62 strike for 0.32 looks cleaner than 60 for 0.28 ngl, IV probably got a bump on the retrace
12.09K
·
08-20
$AMD 20260821 515.0 CALL$ Finally able to afford a bowl of Koh Brothers Pig Organ Soup at Tiong Bahru Hawker Centre. Always Long queue! 😋😋😋 $AMD 20260821 515.0 CALL$
AMD CALL
08-20 21:46
US20260821 515.0
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Buy Close | 0.10 1Lot(s) | +99.01% Closed |
TOPDon't eat too much... high everything 😎😂
1.22K
·
08-20
8/20 Pre-Market Thoughts: Hard Assets Rampage
One-sentence theme: A massive rotation is underway — gold at 4,500, crude oil +3%, bitcoin short-squeeze rally (hard assets rampage), while U.S. stocks continue to pull back. Fiscal stimulus failed to suppress long-end rates, and risk appetite has shifted toward physical assets. I. Sentiment Focus: Hard Assets Surging Across the Board Gold breaks above 4,500: The U.S. Treasury announced at least a doubling of long-end repurchase scale (injecting liquidity) → gold surged to 4,500. However, pre-market Thursday saw the 30-year Treasury yield rebound sharply, returning to pre-announcement levels → fiscal stimulus failed to suppress long-end rates, and U.S. equities continued their pullback. Crude oil +3%, maintaining strong upward momentum. Bitcoin short squeeze! Surged to 72,000, with $2.7 bi
TOPGold above 4500 still tracks the same setup for me: sticky inflation plus softer real yields. The sharp move can cool off, but dips still look like the cleaner sell put window.
649
·
08-20
$AI Gains 5.17% as Cloud Capex Momentum Sparks a Software Rebound
$C3.ai, Inc.(AI)$ $C3.ai, Inc.(AI) Closes +5.17% at $10.38: AI Software Play Reclaims $10 Handle, $10.47 Resistance in Sight Latest Close Data: C3.ai finished Wednesday at $10.38 (+5.17%), with intraday range $9.74–$10.41. Price now sits 48.7% below its 52-week high of $20.22, but has bounced sharply from the $7.67 52-week low. Core Market Drivers: Enterprise AI sentiment firmed after peer CoreWeave's blowout earnings reinforced cloud capex strength. Short-covering likely amplified gains, with short volume ratio spiking to 37.91% on 8/18 before easing. No company-specific catalyst hit the tape, leaving the move macro- and momentum-driven. Technical Analysis: Volume hit 4.3329M shares (Volume Ratio 1.04), confirming participation. MACD flipped decisi
1.01K
·
08-20
RBC’s $230 Target Sends $ILMN Surging 8.87%
$Illumina(ILMN)$ Latest Close Data ILMN closed at $205.00 on Aug 20, 2026, up +8.87% (+$16.71) from prior close of $188.29. The stock traded just $2.00 below its 52-week high of $207.00, with intraday range of $192.68–$205.16. After-hours price hit $207.91, already breaching that level. Core Market Drivers RBC Capital Markets reaffirmed "Outperform" with a $230 target, citing accelerating clinical sequencing momentum and fading competitive concerns. Q2 earnings (reported Jul 30) beat on both EPS and revenue, with FY guidance of $45.2B–$46.2B above consensus. Life-science sector strength provided tailwind. Technical Analysis Volume surged to 2.09M shares (Volume Ratio 1.90), confirming institutional accumulation. MACD remains negative at -1.28 (DIF
997
·
08-20
$NFLX Gains 3.15% as Ackman Bet Adds Fuel to the Breakout
$Netflix(NFLX)$ $Netflix(NFLX) +3.15% Reclaims $80 as MACD Golden Cross Ignites Breakout Momentum Latest Close: $80.22 (+3.15%), just 36.7% below its 52-week high of $126.71, with intraday range $78.10–$81.16 on 31.46M shares traded. Core Market Drivers: Bill Ackman's Pershing Square disclosed a new NFLX stake, sparking institutional buying. Netflix also secured 2027 Women's World Cup rights for $200M, reinforcing its live-sports moat. Streaming sentiment stays risk-on. Technical Analysis: MACD histogram surged to +1.59 with DIF crossing firmly above DEA, confirming a fresh golden cross on the daily. RSI(6) at 72.8 signals strong bullish momentum, though approaching overbought. KDJ J-line at 82.8 shows upward extension without bearish divergence y
1.17K
·
08-20
$ADBE Rebounds as AI Software Rotation Fuels a Move Toward $289
$Adobe(ADBE)$ $Adobe (ADBE) +3.55%: AI Monetization Momentum Builds, Pivot Above $272 Targets $289 Reclaim 🎯 Latest Close: $272.47 (+3.55%) | Session Range: $261.67–$275.80 | 52W High: $370.86 Core Market Drivers: BofA upgraded ADBE's target to $220, triggering a se ntiment shift after Morgan Stanley's earlier downgrade. AI application software rotation continues—capital migrating from hardware infrastructure to monetization plays, lifting ADBE alongside CRM. Volume ratio of 1.32 confirms institutional participation. Technical Analysis: 📊 MACD histogram flipped positive (+2.92) with DIF (10.98) crossing above DEA (9.52), signaling bullish momentum. RSI(6) surged to 65.8 from 43.3 in four sessions, exiting oversold territory decisively. KDJ shows K
743
·
08-20
$INTU Rallies Into Q4 Results as the AI Software Trade Reawakens
$Intuit(INTU)$ $Intuit Inc.(INTU) +3.44%: AI Software Momentum Builds, $430 Resistance in Sight Latest Close Data: INTU closed at $362.47 (+3.44%) on Aug 20, with intraday range $349.32–$365.38. Still 49.6% below 52-week high of $719.10, but up 43.3% from 52-week low of $252.84. Core Market Drivers: AI application software sector continued its strong rebound, with peer strength lifting INTU ahead of its Aug 25 Q4 earnings release. Market consensus expects revenue of ~$4.27B (+13.95% YoY) and adjusted EPS of $3.58 (+34.66%), fueling pre-earnings accumulation. Citi recently maintained Buy with $457 target despite trimming from $591. Technical Analysis: MACD shows DIF 15.02 > DEA 12.44 with positive histogram 5.15, confirming bullish momentum. RSI
587
·
08-20
$UAA Rallies 3.55% as Short Interest Adds Fuel to the Rebound
$Under Armour Class A(UAA)$ $Under Armour (UAA) +3.55%: Oversold Rebound Ignites, $6.21 Resistance Test Looms Latest Close: $5.25 (+3.55%) | Amplitude 3.85% | Vol 10.42M (VR 1.22) | 52W Range: $4.13–$8.15 | Distance from 52W High: -35.6% Core Market Drivers: Short-covering dominated as UAA bounced from multi-week lows near $5.08 support. No company-specific catalyst; broader retail sentiment stabilized, while insider ownership remains anchored by Kevin Plank (12.91%) and BDT Capital (15.51%), limiting float-driven downside. Technical Analysis: Volume Ratio at 1.22 confirms active accumulation. MACD remains deeply negative (DIF -0.400, DEA -0.248, Histogram -0.303) — still bearish but histogram contraction hints at slowing downside momentum. RSI(6)
9.74K
·
08-20
Moderna Soars 177%: Has the First Personalized mRNA Cancer Therapy Arrived?
$Moderna, Inc.(MRNA)$Moderna and Merck’s personalized cancer therapy met its key goals in a Phase 3 melanoma trial, sending MRNA sharply higher and lifting the broader biotech sector. Biotech stocks have finally found a major catalyst. Moderna (MRNA) surged roughly 177%, while Merck (MRK) gained about 12.6%. BioNTech (BNTX), which is also developing mRNA-based cancer treatments, climbed nearly 22%. Biotech ETFs XBI and IBB rose about 5.9% and 6.6%, respectively. The catalyst was positive Phase 3 data for intismeran autogene, also known as V940 or mRNA-4157. The personalized mRNA therapy is being jointly developed by Moderna and Merck and tested in combination with Merck’s blockbuster immunotherapy drug Keytruda. The combination met
TOPOpportunity for the companiesModerna: High impact. Post-COVID revenue collapse left it needing a new growth engine. This de-risks the mRNA oncology platform and is one of its three planned commercial franchises. Melanoma peak sales estimates for the therapy (total, before split) are roughly $1–3+ billion (Barclays ~$3B by 2035; other views in the $1.4–2.5B range for melanoma). Moderna’s share is half. Bigger upside lies in ongoing trials (NSCLC, renal cell, bladder, etc.); optimistic analyst views (e.g., BofA unadjusted global peak ~$54B across indications; William Blair multi-billion to Moderna in NSCLC/RCC) treat it as potentially Keytruda-like in breadth. It helps path back to profitability and validates the platform for other programs. Stock roughly more than doubled (peaks ~150–177%), adding tens of billions in market cap (to ~$50–70B range before some profit
661
·
08-20
$PFE Rallies 3.63% as Lyme Vaccine Approval Pushes Shares Toward a 52-Week High
$Pfizer(PFE)$ $Pfizer (PFE)+3.63% Surge Nears 52-Week High, RSI Overbought Signal Flashes Latest Close: $28.24 (+3.63%), just $0.51 from 52-week high of $28.75. Volume 59.8M shares (1.93x avg ratio). Core Drivers: EMA approved Pfizer-Valneva Lyme disease vaccine application, igniting momentum. Broad pharma sentiment lifted by Moderna-Merck mRNA cancer vaccine Phase 3 success. Pfizer trades near multi-year highs on pipeline optimism. Technical Analysis: RSI(6) at 86.1 and RSI(12) at 77.6 — firmly overbought, signaling strong momentum but elevated pullback risk. MACD bullish with DIF 0.668 > DEA 0.474, histogram expanding at 0.388. KDJ-J at 93.3 confirms overbought extreme. Key Price Levels: Primary Support $27.58 (today's low), Strong Resistance